Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;34:782-789

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frohlich, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frohlich, E. D.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*High Blood Pressure

(Hypertension. 1999;34:782-789.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Risk Mechanisms in Hypertensive Heart Disease

Edward D. Frohlich, MD

From the Alton Ochsner Medical Foundation, New Orleans, La.

Correspondence to Edward D. Frohlich, MD, Alton Ochsner Distinguished Scientist, Vice President for Academic Affairs, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy, New Orleans, LA 70121.

Abstract—In this report, some of the underlying pathophysiological alterations associated with the independent risk from hypertensive heart disease and left ventricular hypertrophy are discussed. Emphasized are the classically described coronary hemodynamic alterations of decreased coronary blood flow and flow reserve with increased coronary vascular resistance and minimal coronary resistance; more recent concepts of endothelial dysfunction are emphasized. Additionally, increased collagen deposition within the ventricular walls and perivascularly participates importantly. These changes are exacerbated by the aging process and perhaps by increased dietary salt intake. Consequences of these functional and structural changes include further endothelial dysfunction, impairment of coronary hemodynamics, and ventricular contractile function (diastolic as well as systolic). The clinical consequences of these alterations are angina pectoris (with or without atherosclerosis), myocardial infarction, cardiac failure, lethal dysrhythmias, and sudden cardiac death. Thus, not all that is clinically recognized as "left ventricular hypertrophy" is true myocytic hypertrophy with structural remodeling; other important comorbid changes occur that directly affect risk, including ventricular fibrosis, impaired coronary hemodynamics, and endothelial dysfunction.


Key Words: left ventricular hypertrophy • coronary heart disease • coronary hemodynamics • fibrosis • sudden death • risk




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Bolte, G. Newman, and J. E. J. Schultz
Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac {kappa}-opioid receptor stimulation
Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H967 - H975.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. L. Muiesan, M. Salvetti, A. Paini, C. Agabiti-Rosei, C. Monteduro, G. Galbassini, E. Belotti, C. Aggiusti, D. Rizzoni, M. Castellano, et al.
Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism
Hypertension, September 1, 2008; 52(3): 529 - 534.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
R Rajab, E Stearns, and S Baithun
Autopsy pathology of cocaine users from the Eastern district of London: a retrospective cohort study
J. Clin. Pathol., July 1, 2008; 61(7): 848 - 850.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Varagic, E. D. Frohlich, D. Susic, J. Ahn, L. Matavelli, B. Lopez, and J. Diez
AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H853 - H858.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti
Review: New approaches to the assessment of left ventricular hypertrophy
Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 119 - 128.
[Abstract] [PDF]


Home page
HypertensionHome page
E. D. Frohlich
The Salt Conundrum: A Hypothesis
Hypertension, July 1, 2007; 50(1): 161 - 166.
[Full Text] [PDF]


Home page
HypertensionHome page
M. L. Muiesan, M. Salvetti, A. Paini, C. Monteduro, G. Galbassini, B. Bonzi, P. Poisa, E. Belotti, C. Agabiti Rosei, D. Rizzoni, et al.
Inappropriate Left Ventricular Mass Changes During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients
Hypertension, May 1, 2007; 49(5): 1077 - 1083.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley
Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy
Cardiovasc Res, January 15, 2007; 73(2): 257 - 268.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. A. Pfeffer and E. D. Frohlich
Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
G. Mancia, F. Scopelliti, and G. Grassi
Hypertension and the Heart.
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 198 - 202.
[Abstract] [PDF]


Home page
HypertensionHome page
M. C. C. Borges, R. C.R. Colombo, J. G. F. Goncalves, J. d. O. Ferreira, and K. G. Franchini
Longitudinal Mitral Annulus Velocities Are Reduced in Hypertensive Subjects With or Without Left Ventricle Hypertrophy
Hypertension, May 1, 2006; 47(5): 854 - 860.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti
Evaluation of Subclinical Target Organ Damage for Risk Assessment and Treatment in the Hypertensive Patients: Left Ventricular Hypertrophy
J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S104 - S108.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor
Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases
Physiol Rev, April 1, 2005; 85(2): 679 - 715.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Ahn, J. Varagic, M. Slama, D. Susic, and E. D. Frohlich
Cardiac structural and functional responses to salt loading in SHR
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H767 - H772.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. A. Albert, J. Torres, R. J. Glynn, and P. M Ridker
Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans
Circulation, July 13, 2004; 110(2): e7 - e12.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. D. Frohlich
Left ventricular hypertrophy: a "factor of risk": Mass is reversible, but is the risk?
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2216 - 2218.
[Full Text] [PDF]


Home page
HypertensionHome page
M. L. Muiesan, M. Salvetti, C. Monteduro, B. Bonzi, A. Paini, S. Viola, P. Poisa, D. Rizzoni, M. Castellano, and E. Agabiti-Rosei
Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients
Hypertension, April 1, 2004; 43(4): 731 - 738.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Kozakova, G. de Simone, C. Morizzo, and C. Palombo
Coronary Vasodilator Capacity and Hypertension-Induced Increase in Left Ventricular Mass
Hypertension, February 1, 2003; 41(2): 224 - 229.
[Abstract] [Full Text] [PDF]


Home page
Int J EpidemiolHome page
G MacGregor and H. de Wardener
Commentary: Salt, blood pressure and health
Int. J. Epidemiol., April 1, 2002; 31(2): 320 - 327.
[Full Text] [PDF]


Home page
HypertensionHome page
G. Grassi, G. Seravalle, G. Bertinieri, M. L. Stella, C. Turri, and G. Mancia
Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure
Hypertension, April 1, 2002; 39(4): 886 - 891.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. D. Frohlich
Local Hemodynamic Changes in Hypertension: Insights for Therapeutic Preservation of Target Organs
Hypertension, December 1, 2001; 38(6): 1388 - 1394.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
K E Berkin and S G Ball
HYPERTENSION: Essential hypertension: the heart and hypertension
Heart, October 1, 2001; 86(4): 467 - 475.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Bell, S. I. Mosfer, D. Lang, F. Donaldson, and M. J. Lewis
Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1704 - H1710.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
A. S. Khan, C. D. Lynch, D. C. Sane, M. C. Willingham, and W. E. Sonntag
Growth Hormone Increases Regional Coronary Blood Flow and Capillary Density in Aged Rats
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2001; 56(8): B364 - 371.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Varagic, D. Susic, and E. D. Frohlich
Coronary Hemodynamic and Ventricular Responses to Angiotensin Type 1 Receptor Inhibition in SHR : Interaction With Angiotensin Type 2 Receptors
Hypertension, June 1, 2001; 37(6): 1399 - 1403.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. Varagic, D. Susic, and E. D. Frohlich
Cardiovasc Pharmacol Therapeut 6(1):57-63, 2001 Low-Dose ACE with Alphaor Beta-Adrenergic Receptor Inhibitors Have Beneficial SHR Cardiovascular Effects
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 57 - 63.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
E. D Frohlich
Review: Promise of prevention and reversal of target organ involvement in hypertension
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S4 - S9.
[PDF]


Home page
HypertensionHome page
R. Zeltner, C. Delles, M. Schneider, W. Siffert, and R. E. Schmieder
G-Protein {beta}3 Subunit Gene (GNB3) 825T Allele Is Associated With Enhanced Renal Perfusion in Early Hypertension
Hypertension, March 1, 2001; 37(3): 882 - 886.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Susic, J. Varagic, and E. D. Frohlich
Abnormal Renal Vascular Responses to Dipyridamole-Induced Vasodilation in Spontaneously Hypertensive Rats
Hypertension, March 1, 2001; 37(3): 894 - 897.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. M. Perry, E. D. Freis, and E. D. Frohlich
Department of Veterans Affairs Hypertension Meeting : A Proposal for Improved Care
Hypertension, April 1, 2000; 35(4): 853 - 857.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Dodic, C. Samuel, K. Moritz, E. M. Wintour, J. Morgan, L. Grigg, and J. Wong
Impaired Cardiac Functional Reserve and Left Ventricular Hypertrophy in Adult Sheep After Prenatal Dexamethasone Exposure
Circ. Res., September 28, 2001; 89(7): 623 - 629.
[Abstract] [Full Text] [PDF]